Engineering cardiac tissue in vivo from human adipose-derived stem cells
Engineering cardiac tissue in vivo from human adipose-derived stem cells
复制标题
DOI：
10.1016/j.biomaterials.2009.11.097
复制
发表时间：
2010-03-01
期刊：
影响因子：
14
通讯作者：
Dilley, Rodney J.
中科院分区：
文献类型：
--
作者：
Choi, Yu Suk;Matsuda, Ken;Dilley, Rodney J.
心脏组织工程为心脏修复提供了一种外科方法，但需要足够的心肌细胞来源。在这里，我们通过将脂肪来源干细胞（ASC）与诱导大鼠心肌细胞（rCM）共同植入血管化组织工程室，评估了在体内从脂肪来源干细胞（ASC）生成人心肌细胞的潜力。6周后比较共植入（ASC-rCM）与单独ASC对照。利用人核特异性抗体和心脏标记物进行免疫染色，揭示了房内ASC的几种命运；(1)分化为心肌细胞并与共植入rCM整合；(2)分化为平滑肌细胞并招募到血管结构；(3)成脂分化。ASC-rCM组和ASC组比单独rCM组生长更大的组织结构（212 +/- 25 μ l， 171 +/- 16 μ l和137 +/- 15 μ l）。ASC-rCM组和rCM组自发收缩速度高达140 bpm，产生的心肌体积（14.5 +/- 4.8 μ l和18.5 +/- 2.6 μ l）比ASC单独组（1.3 +/- 0.5 μ l）大10-15倍。ASC-rCM组血管体积是rCM组的2倍（28.7 +/- 5.0 μ l vs. 14.8 +/- 1.8 μ l）。新生儿rCM与人ASC共植入的心脏组织显示出ASC的体内可塑性及其在组织工程中的成心潜能。ASC对血管化的贡献也促进了工程组织的生长，证实了它们在这种情况下的效用。2009爱思唯尔有限公司版权所有。
Cardiac tissue engineering offers promise as a surgical approach to cardiac repair, but requires an adequate source of cardiomyocytes. Here we evaluate the potential for generating human cardiac muscle cells in vivo from adipose-derived stem cells (ASC) by co-implanting in a vascularised tissue engineering chamber with inducing rat cardiomyocytes (rCM). Co-implantation (ASC-rCM) was compared with rCM or ASC controls alone after 6 weeks. Immunostaining using human nucleus specific antibody and cardiac markers revealed several fates for ASC in the chamber; (1) differentiation into cardiomyocytes and integration with co-implanted rCM; (2) differentiation into smooth muscle cells and recruitment into vascular structures; (3) adipogenic differentiation. ASC-rCM and ASC groups grew larger tissue constructs than rCM alone (212 +/- 25 mu l, 171 +/- 16 mu l vs. 137 +/- 15 mu l). ASC-rCM and rCM groups contracted spontaneously at up to 140 bpm and generated a 10-15-fold larger volume of cardiac muscle (14.5 +/- 4.8 mu l and 18.5 +/- 2.6 mu l) than ASC alone group (1.3 +/- 0.5 mu l). Vascular volume in ASC-rCM group was twice that of the rCM group (28.7 +/- 5.0 mu l vs. 14.8 +/- 1.8 mu l). The cardiac tissue engineered by co-implanting human ASC with neonatal rCM showed in vivo plasticity of ASC and their cardiomyogenic potential in tissue engineering. ASC contribution to vascularisation also promoted the growth of engineered tissue, confirming their utility in this setting. (C) 2009 Elsevier Ltd. All rights reserved.